troglitazone has been researched along with Pregnancy in 26 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that the administration of troglitazone, an insulin-sensitizing agent of the thiazolidinedione class, would improve the ovulatory dysfunction, hirsutism, hyperandrogenemia, and hyperinsulinemia of polycystic ovary syndrome (PCOS) patients." | 9.09 | Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. ( Azziz, R; Ehrmann, D; Fereshetian, AG; Ghazzi, MN; Hanley, R; Legro, RS; O'Keefe, M; Whitcomb, RW, 2001) |
| "To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy." | 7.70 | Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. ( Elkind-Hirsch, KE; McWilliams, RB, 1999) |
| " Oral glucose tolerance tests (OGTTs) and frequently sampled intravenous glucose tolerance tests (FSIGTs) were conducted on Latino women with impaired glucose tolerance and a history of gestational diabetes before and after 12 weeks of treatment with 400 mg/day troglitazone (n = 13) or placebo (n = 12)." | 5.09 | Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. ( Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Xiang, AH, 2000) |
| "We hypothesized that the administration of troglitazone, an insulin-sensitizing agent of the thiazolidinedione class, would improve the ovulatory dysfunction, hirsutism, hyperandrogenemia, and hyperinsulinemia of polycystic ovary syndrome (PCOS) patients." | 5.09 | Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. ( Azziz, R; Ehrmann, D; Fereshetian, AG; Ghazzi, MN; Hanley, R; Legro, RS; O'Keefe, M; Whitcomb, RW, 2001) |
| "We conducted a randomized placebo-controlled study to determine the effects of the thiazolidinedione compound troglitazone on whole-body insulin sensitivity (SI), pancreatic beta-cell function, and glucose tolerance in 42 Latino women with impaired glucose tolerance (IGT) and a history of gestational diabetes mellitus (GDM), characteristics that carry an 80% risk of developing NIDDM within 5 years." | 5.08 | Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. ( Azen, S; Berkowitz, K; Buchanan, TA; Dunn, ME; Goico, J; Kjos, SL; Marroquin, A; Peters, R; Xiang, A, 1996) |
| "To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy." | 3.70 | Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. ( Elkind-Hirsch, KE; McWilliams, RB, 1999) |
| "Treatment with troglitazone delayed or prevented the onset of type 2 diabetes in high-risk Hispanic women." | 2.70 | Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. ( Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Hodis, HN; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Tan, S; Xiang, AH, 2002) |
| " The primary aim of the TRIPOD trial is to test the hypothesis that chronic administration of troglitazone to nondiabetic women with prior gestational diabetes mellitus (GDM) will improve whole-body insulin sensitivity and reduce the incidence of non-insulin-dependent diabetes (NIDDM)." | 2.69 | TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. ( Azen, SP; Berkowitz, K; Buchanan, TA; Kjos, S; Peters, RK; Xiang, A, 1998) |
| "Women with a history of gestational diabetes mellitus (GDM) are at increased risk of future development of type 2 diabetes." | 1.39 | Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score. ( Cho, NH; Cho, YM; Choi, SH; Jang, HC; Jung, HS; Kim, K; Kim, SY; Kwak, SH; Lim, S; Park, KS, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 16 (61.54) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Lane, SL | 1 |
| Doyle, AS | 1 |
| Bales, ES | 1 |
| Houck, JA | 1 |
| Lorca, RA | 1 |
| Moore, LG | 1 |
| Julian, CG | 1 |
| Frew, L | 1 |
| Sugiarto, NU | 1 |
| Rajagopal, SP | 1 |
| He, J | 1 |
| Leask, R | 1 |
| Norman, JE | 1 |
| Riley, SC | 1 |
| Stock, SJ | 1 |
| Kwak, SH | 1 |
| Choi, SH | 1 |
| Kim, K | 1 |
| Jung, HS | 1 |
| Cho, YM | 1 |
| Lim, S | 1 |
| Cho, NH | 1 |
| Kim, SY | 1 |
| Park, KS | 1 |
| Jang, HC | 1 |
| Stanton, LA | 1 |
| Li, JR | 1 |
| Beier, F | 1 |
| Ruebner, M | 1 |
| Langbein, M | 1 |
| Strissel, PL | 1 |
| Henke, C | 1 |
| Schmidt, D | 1 |
| Goecke, TW | 1 |
| Faschingbauer, F | 1 |
| Schild, RL | 1 |
| Beckmann, MW | 1 |
| Strick, R | 1 |
| Buchanan, TA | 5 |
| Xiang, AH | 3 |
| Peters, RK | 4 |
| Kjos, SL | 4 |
| Marroquin, A | 4 |
| Goico, J | 4 |
| Ochoa, C | 3 |
| Tan, S | 1 |
| Berkowitz, K | 4 |
| Hodis, HN | 2 |
| Azen, SP | 3 |
| Lappas, M | 1 |
| Permezel, M | 1 |
| Georgiou, HM | 1 |
| Rice, GE | 1 |
| Solignac, M | 1 |
| Schröder, AK | 1 |
| Tauchert, S | 1 |
| Ortmann, O | 1 |
| Diedrich, K | 1 |
| Weiss, JM | 1 |
| Asami-Miyagishi, R | 1 |
| Iseki, S | 1 |
| Usui, M | 1 |
| Uchida, K | 1 |
| Kubo, H | 1 |
| Morita, I | 1 |
| Elchalal, U | 1 |
| Humphrey, RG | 1 |
| Smith, SD | 1 |
| Hu, C | 1 |
| Sadovsky, Y | 1 |
| Nelson, DM | 1 |
| Li, SJ | 2 |
| Shang, T | 2 |
| Li, SY | 2 |
| Li, QL | 2 |
| Chang, ZQ | 1 |
| Li, J | 1 |
| Rui, GH | 1 |
| Kawakubo, M | 1 |
| Liu, CR | 1 |
| Liu, CH | 1 |
| Peters, R | 1 |
| Dunn, ME | 1 |
| Xiang, A | 2 |
| Azen, S | 1 |
| Nightingale, SL | 1 |
| Kjos, S | 1 |
| Elkind-Hirsch, KE | 1 |
| McWilliams, RB | 1 |
| Mitwally, MF | 1 |
| Kuscu, NK | 1 |
| Yalcinkaya, TM | 1 |
| Diamanti-Kandarakis, E | 1 |
| Zapanti, E | 1 |
| Pedraza, N | 1 |
| Solanes, G | 1 |
| Iglesias, R | 1 |
| Vázquez, M | 1 |
| Giralt, M | 1 |
| Villarroya, F | 1 |
| Azziz, R | 1 |
| Ehrmann, D | 1 |
| Legro, RS | 1 |
| Whitcomb, RW | 1 |
| Hanley, R | 1 |
| Fereshetian, AG | 1 |
| O'Keefe, M | 1 |
| Ghazzi, MN | 1 |
| Malacara, JM | 1 |
| Fajardo, ME | 1 |
| Nava, LE | 1 |
| Landman, RE | 1 |
| Jacobs, TP | 1 |
| Laboureau-Soares Barbosa, S | 1 |
| Rodien, P | 1 |
| Rohmer, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effect of Gain on Closed-Loop Insulin[NCT02065895] | 8 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Glucose Area Under the Curve (AUC) Breakfast defines the total exposure to glucose during breakfast. Breakfast is typically considered the most difficult meal to control; low AUC is desirable.This outcome measure was analyzed for each of the three calibration error values (high error, no error and low error). (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 2:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
| Intervention | mmol/l/min (Mean) |
|---|---|
| HIGH Error | 66.8 |
| NO Error | 48.8 |
| LOW Error | 37.4 |
Night-time in target range 5.0-8.33, following the 3 hour controller initialization period blood glucose remained at or near target. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 12:00 AM to 6:00 AM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
| Intervention | percentage of time in target range (Median) |
|---|---|
| HIGH Error | 88 |
| NO Errror | 100 |
| LOW Error | 80 |
Highest and lowest glucose concentrations obtained during breakfast meal. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 12:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Peak glucose concentration | Nadir glucose concentration | |
| Gain Decreased and Target Increased | 11.3 | 6.6 |
| Gain Increased and Target Decreased | 13.3 | 4.5 |
| Nadir Mean | 11.8 | 4.8 |
2 reviews available for troglitazone and Pregnancy
| Article | Year |
|---|---|
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
[Polycystic ovary syndrome: treatment with insulin-sensitizing agents].
Topics: Androgens; Chromans; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing | 2002 |
7 trials available for troglitazone and Pregnancy
| Article | Year |
|---|---|
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Double-Blind Method; Female; Gluc | 2002 |
Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes.
Topics: Adult; Carotid Artery Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease | 2008 |
Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; California; Cholesterol, HDL; Cholesterol, LD | 1996 |
TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.
Topics: Adolescent; Adult; Blood Glucose; Carotid Stenosis; Chromans; Diabetes Mellitus, Type 2; Double-Blin | 1998 |
Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose; Glucose Intolera | 2000 |
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
Topics: Adult; Androgens; Blood Glucose; Chromans; Dose-Response Relationship, Drug; Double-Blind Method; Fe | 2001 |
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
Topics: Adult; Androgens; Blood Glucose; Chromans; Dose-Response Relationship, Drug; Double-Blind Method; Fe | 2001 |
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
Topics: Adult; Androgens; Blood Glucose; Chromans; Dose-Response Relationship, Drug; Double-Blind Method; Fe | 2001 |
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
Topics: Adult; Androgens; Blood Glucose; Chromans; Dose-Response Relationship, Drug; Double-Blind Method; Fe | 2001 |
Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens.
Topics: Chromans; Clomiphene; Estrogens; Feedback, Physiological; Female; Follicle Stimulating Hormone; Gona | 2001 |
17 other studies available for troglitazone and Pregnancy
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor gamma blunts endothelin-1-mediated contraction of the uterine artery in a murine model of high-altitude pregnancy.
Topics: Animals; Disease Models, Animal; Endothelin-1; Female; Fetal Growth Retardation; Hypoxia; Immunohist | 2020 |
The effect of omega-3 polyunsaturated fatty acids on the inflammatory response of the amnion.
Topics: Amnion; Anilides; Anti-Inflammatory Agents; Chromans; Cytokines; Drug Evaluation, Preclinical; Fatty | 2013 |
Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Progression; Female; Foll | 2013 |
PPARgamma2 expression in growth plate chondrocytes is regulated by p38 and GSK-3.
Topics: Animals; Bone Development; Cell Differentiation; Cells, Cultured; Chondrocytes; Chromans; Embryo, Ma | 2010 |
Regulation of the human endogenous retroviral Syncytin-1 and cell-cell fusion by the nuclear hormone receptors PPARγ/RXRα in placentogenesis.
Topics: Alitretinoin; Cell Fusion; Cell Line; Chromans; Cyclic AMP-Dependent Protein Kinases; Endogenous Ret | 2012 |
Regulation of proinflammatory cytokines in human gestational tissues by peroxisome proliferator-activated receptor-gamma: effect of 15-deoxy-Delta(12,14)-PGJ(2) and troglitazone.
Topics: Amnion; Chorion; Chromans; Culture Techniques; Decidua; DNA; Female; Humans; Interleukin-6; Interleu | 2002 |
[News on diabetes and public health perspectives].
Topics: Administration, Oral; Adult; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitu | 2002 |
Expression and function of PPARgamma in rat placental development.
Topics: Administration, Oral; Animals; Body Weight; Cell Differentiation; Chromans; DNA; Ear, Inner; Female; | 2004 |
Troglitazone attenuates hypoxia-induced injury in cultured term human trophoblasts.
Topics: Apoptosis; Blotting, Western; Cell Hypoxia; Cells, Cultured; Chromans; Female; Gestational Age; Huma | 2004 |
[Effects of peroxisome proliferator-activated receptor gamma and its ligands on cytotrophoblast invasion in first trimester of pregnancy and mechanism thereof].
Topics: Adult; Cell Movement; Cells, Cultured; Chromans; Female; Humans; Immunohistochemistry; Ligands; Matr | 2007 |
[Effect of peroxisome proliferators-activated receptor gamma ligands on cytotrophoblast invasion in first trimester pregnancy].
Topics: Adult; Cell Movement; Cells, Cultured; Chorionic Villi; Chromans; Female; Gene Expression Regulation | 2007 |
From the Food and Drug Administration.
Topics: Animals; Antioxidants; Chromans; Computer Communication Networks; Drug Labeling; Drug Monitoring; Fe | 1998 |
Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome.
Topics: Acanthosis Nigricans; Adult; Blood Glucose; Chromans; Female; Gonadal Steroid Hormones; Humans; Hypo | 1999 |
High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome.
Topics: Adult; Body Temperature; Chromans; Clomiphene; Drug Resistance; Female; Humans; Infertility, Female; | 1999 |
Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome.
Topics: Androgen Antagonists; Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; | 2000 |
Differential regulation of expression of genes encoding uncoupling proteins 2 and 3 in brown adipose tissue during lactation in mice.
Topics: Adipose Tissue, Brown; Animals; Bezafibrate; Carrier Proteins; Chromans; Dietary Fats; Female; Gene | 2001 |
Troglitazone use in polycystic ovary syndrome.
Topics: Chromans; Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Polycystic | 2001 |